Mo1746 Human-Leukocyte Antigen Type Is Associated With Duration on Infliximab Therapy in Patients With Antibodies to Infliximab

Autor:	Thomas Billiet, Isabelle Cleynen, Sharat Singh, Marc Ferrante, Severine Vermeire, Karolien Claes, Fred Princen, Ann Gils, Gert A. Van Assche, Niels Vande Casteele, Thomas Van Stappen, Vera Ballet
Rok vydání:	2015
Předmět:	medicine.medical_specialty Hepatology biology business.industry Surrogate endpoint Multiple sclerosis Immunogenicity Gastroenterology Albumin medicine.disease Loading dose Concomitant Internal medicine biology.protein Medicine Antibody Allele business
Zdroj:	Gastroenterology. 148:S-701
ISSN:	0016-5085
DOI:	10.1016/s0016-5085(15)32376-3
Popis:	Inc.). Patient and therapy factors and the number of allele carriers for the different DRB1 alleles were compared between cases and controls. Stepwise logistic regression was performed to identify independent predictors of ATI formation. Results At IFX start, a loading dose (at weeks 0-2-6) and a higher albumin level were protective for ATI formation (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b6ac704b10cd471086c5978a7755e93e https://doi.org/10.1016/s0016-5085(15)32376-3 Zobrazit plný text záznamu